GeneDx Holdings Corp. Class A Common Stock (WGS) — Analysis Summary
GeneDx Holdings Corp. Class A Common Stock (WGS) has a market cap of $1.90B with year-over-year revenue growth of +40.0%. Net margin stands at -4.9%. The stock trades at a P/E ratio of -17.9.
Key Takeaways
- Revenue changed +40.0% year-over-year
- Net margin of -4.9%
- P/E ratio of -17.9
Compared to other companies in the SERVICES-HEALTH SERVICES sector, WGS posted revenue growth of +40.0% and trades at a P/E of -17.9.
GeneDx Holdings Corp. Class A Common Stock (WGS)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -20.3% — material operating losses
Net margin at -23.4% — significant losses
Net income fell 406.0% vs the prior period.
Free cash flow turned negative after being positive in the prior period.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Sector
SERVICES-HEALTH SERVICES
Employees
1,300
Headquarters
STAMFORD, CT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.